Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 23, 2017

Study Completion Date

August 23, 2017

Conditions
Lung Transplant InfectionLower Respiratory Tract Infection
Interventions
DRUG

Dornase Alfa

Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.

DRUG

Isotonic Saline.

Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.

Trial Locations (1)

3000

The Alfred, Melbourne

All Listed Sponsors
collaborator

The Alfred Research Trusts Small Project Grant.

UNKNOWN

collaborator

Dr Carey Denholm and Laura Denholm

UNKNOWN

lead

The Alfred

OTHER

NCT01952470 - Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant. | Biotech Hunter | Biotech Hunter